ArticleInternational journal of radiation biology
alpha6 integrin cleavage: sensitizing human prostate cancer to ionizing radiation.
Article in International journal of radiation biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Beyond DNA damage: 3D tumor models and the integrin mechanobiology of radioresistance.Journal of experimental & clinical cancer research : CR · 2026Review
- Evaluation of Extracellular Matrix Composition to Improve Breast Cancer Modeling.Tissue engineering. Part A · 2021Article
- Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.American journal of clinical and experimental urology · 2019Article
- Integrin α6/Akt/Erk signaling is essential for human breast cancer resistance to radiotherapy.Scientific reports · 2016Article
- Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy.International journal of molecular sciences · 2015Review
- The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Frontiers in oncology · 2014Review
- Integrin α3β1 regulates tumor cell responses to stromal cells and can function to suppress prostate cancer metastatic colonization.Clinical & experimental metastasis · 2013Article
- Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2012Article
- Metastasis Update: Human Prostate Carcinoma Invasion via Tubulogenesis.Prostate cancer · 2011Article
- Integrin involvement in freeze resistance of androgen-insensitive prostate cancer.Prostate cancer and prostatic diseases · 2010Article
- Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis.Cancer research · 2009Article
- Bicalutamide inhibits androgen-mediated adhesion of prostate cancer cells exposed to ionizing radiation.The Prostate · 2008Article
- Integrins in prostate cancer progression.Endocrine-related cancer · 2008Review
- Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention.Expert review of anticancer therapy · 2008Review
- The role of alpha 6 integrin in prostate cancer migration and bone pain in a novel xenograft model.PloS one · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThe goal was to determine if prostate tumor cells containing a mutant alpha6 integrin would be defective in tumor re-population following clinically relevant fractionated ionizing radiation (IR) treatments. MATERIAL AND
methodsHuman prostate cancer cells derived from PC3N cells were used which conditionally expressed a cleavable, wild type form of alpha6 integrin (PC3N-alpha6-WT) or a mutated non-cleavable form of alpha6 integrin (PC3N-alpha6-RR). The resulting tumor growth before, during and after fractionated doses of IR (3 Gyx10 days) was analyzed using the endpoints of tumor growth inhibition (T/C), tumor growth delay (T-C), tumor doubling time (Td) and tumor cell kill (Log(10) cell kill).
resultsThe T/C values were 36.1% and 39.5%, the T-C values were 20.5 days and 28.5 days and the Td values were 5.5 and 10.5 days for the irradiated PC3N-alpha6-WT and PC3N-alpha6-RR cells, respectively. The Log(10) was 1.1 for the PC3N-alpha6-WT cells and 0.8 for the PC3N-alpha6-RR cells. The tumor response to IR was altered in tumors expressing the mutant alpha6 integrin as indicated by a significant increase in tumor growth inhibition, an increase in tumor growth delay, an increase in tumor doubling time and an increase in tumor cell kill.
conclusionsBlocking integrin cleavage in vivo may be efficacious for increasing the IR responsiveness of slow growing, pro-metastatic human prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.